For help on how to get the results you want, see our search tips.
45 results
Medicine
Shortages Remove Shortages filter
Summaries of opinion Remove Summaries of opinion filter
Direct healthcare professional communication Remove Direct healthcare professional communication filter
Medicine type
Orphan medicine Remove Orphan medicine filter
Additional monitoring Remove Additional monitoring filter
Exceptional circumstances Remove Exceptional circumstances filter
Biosimilar Remove Biosimilar filter
Categories
Human Remove Human filter
-
List item
Summary of opinion: Nexviadyme (updated)
Avalglucosidase alfa, opinion date: 23/07/2021, Positive, Last updated: 02/08/2021 -
List item
Summary of opinion: Flynpovi (updated)
eflornithine, sulindac, opinion date: 24/06/2021, Negative, Last updated: 23/07/2021 -
List item
Summary of opinion: Abevmy
bevacizumab, opinion date: 25/02/2021, Positive, Last updated: 26/02/2021 -
List item
Summary of opinion: Lextemy
bevacizumab, opinion date: 25/02/2021, Positive, Last updated: 26/02/2021 -
List item
Summary of opinion: Trelegy Ellipta
fluticasone furoate, umeclidinium, vilanterol, opinion date: 25/02/2021, Negative, Last updated: 26/02/2021 -
List item
Summary of opinion: Elebrato Ellipta
fluticasone furoate, umeclidinium, vilanterol, opinion date: 25/02/2021, Negative, Last updated: 26/02/2021 -
List item
Summary of opinion: Temybric Ellipta
fluticasone furoate, umeclidinium, vilanterol, opinion date: 25/02/2021, Negative, Last updated: 26/02/2021 -
List item
Summary of opinion: Koselugo
selumetinib, opinion date: 22/04/2021, Positive, Last updated: 23/04/2021 -
List item
Summary of opinion: Galafold
migalastat, opinion date: 24/06/2021, Positive, Last updated: 25/06/2021 -
List item
Summary of opinion: Rinvoq
upadacitinib, opinion date: 24/06/2021, Positive, Last updated: 25/06/2021 -
List item
Summary of opinion: Xeljanz
tofacitinib, opinion date: 24/06/2021, Positive, Last updated: 25/06/2021 -
List item
Summary of opinion: Voxzogo
vosoritide, opinion date: 24/06/2021, Positive, Last updated: 25/06/2021 -
List item
Summary of opinion: Minjuvi
tafasitamab, opinion date: 24/06/2021, Positive, Last updated: 25/06/2021 -
List item
Summary of opinion: Byooviz
ranibizumab, opinion date: 24/06/2021, Positive, Last updated: 24/06/2021 -
List item
Summary of opinion: Abecma
idecabtagene vicleucel, opinion date: 24/06/2021, Positive, Last updated: 25/06/2021 -
List item
Summary of opinion: Spherox
spheroids of human autologous matrix-associated chondrocytes, opinion date: 20/05/2021, Positive, Last updated: 21/05/2021 -
List item
Summary of opinion: Keytruda
pembrolizumab, opinion date: 20/05/2021, Positive, Last updated: 21/05/2021 -
List item
Summary of opinion: Vosevi (new)
sofosbuvir, velpatasvir, voxilaprevi, opinion date: 22/07/2021, Positive, Last updated: 23/07/2021 -
List item
Summary of opinion: Deltyba (new)
delamanid, opinion date: 22/07/2021, Positive, Last updated: 23/07/2021 -
List item
Summary of opinion: Ultomiris (new)
ravulizumab, opinion date: 22/07/2021, Positive, Last updated: 23/07/2021 -
List item
Summary of opinion: Maviret
glecaprevir, pibrentasvir, opinion date: 22/04/2021, Positive, Last updated: 26/04/2021 -
List item
Summary of opinion: Darzalex
daratumumab, opinion date: 20/05/2021, Positive, Last updated: 21/05/2021 -
List item
Direct healthcare professional communication (DHPC): Tecentriq (atezolizumab): Risk of Severe Cutaneous Adverse Reactions (SCARs)
Active substance: atezolizumab, DHPC type: Adverse event, Last updated: 25/03/2021 -
List item
Direct healthcare professional communication (DHPC): Polivy (polatuzumab vedotin) 140 mg powder for concentrate for solution for injection: Important information on plastic vial flip-off cap colour
Active substance: polatuzumab vedotin, DHPC type: Quality defect, Last updated: 04/05/2020 -
List item
Direct healthcare professional communication (DHPC): Ondexxya (andexanet alfa): Commercial anti-FXa activity assays are unsuitable for measuring anti-FXa activity following administration of andexanet alfa
Active substance: andexanet alfa, DHPC type: Safety signal, Last updated: 17/06/2020